SIP
RIGL icon

Stoneridge Investment Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Stoneridge Investment Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,135
Closed -$46K – 149
2024
Q1 		$46K Buy
+3,135
New +$42.3K 0.02% 119

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Stoneridge Investment Partners's RIGL Position: Q2 2024 in Review

Stoneridge Investment Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 3,135 shares — an estimated $46K sold.

Stoneridge Investment Partners first reported a position in RIGL in Q1 2024 and held it in 1 quarter. The position peaked at $46K in Q1 2024. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Stoneridge Investment Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Stoneridge Investment Partners sold 3,135 Rigel Pharmaceuticals shares in Q2 2024, an estimated $46K.
  • Stoneridge Investment Partners first reported a position in Rigel Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Stoneridge Investment Partners's Rigel Pharmaceuticals position peaked at $46K in Q1 2024.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Stoneridge Investment Partners's 13F filing for Q2 2024, filed 8 Aug 2024.